FLT3 and acute myeloid leukemia: In general, FLT3-ITD AML should be considered for allo-HSCT in CR1, but in the subgroup of patients with low allelic ratio and concomitant NPM1 mutation who achieve MRD negativity after induction therapy transplant indication remains controversial [47].